CL2015003787A1 - Compuestos para la formación de pro-drogas - Google Patents

Compuestos para la formación de pro-drogas

Info

Publication number
CL2015003787A1
CL2015003787A1 CL2015003787A CL2015003787A CL2015003787A1 CL 2015003787 A1 CL2015003787 A1 CL 2015003787A1 CL 2015003787 A CL2015003787 A CL 2015003787A CL 2015003787 A CL2015003787 A CL 2015003787A CL 2015003787 A1 CL2015003787 A1 CL 2015003787A1
Authority
CL
Chile
Prior art keywords
compounds
pro
drugs
formation
active agent
Prior art date
Application number
CL2015003787A
Other languages
English (en)
Inventor
Klaus Nickisch
Bindu Santhamma
Gulzar Ahmed
Frederick Meece
Walter Elger
Ralf Wyrwa
Hareesh Nair
Original Assignee
Evestra Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52277568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015003787(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Evestra Inc filed Critical Evestra Inc
Publication of CL2015003787A1 publication Critical patent/CL2015003787A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0088—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 containing unsubstituted amino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J51/00—Normal steroids with unmodified cyclopenta(a)hydrophenanthrene skeleton not provided for in groups C07J1/00 - C07J43/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPUESTOS PROFÁRMACOS DE ESTRUCTURA GENERAL AGENTE ACTIVO-(ÁCIDO)-(ENLAZADOR)-SO2NR1R2, DONDE DICHO AGENTE ACTIVO CORRESPONDE A ANDRÓGENOS, ESTRÓGENOS, PROGESTINAS, ENTRE OTROS Y COMPOSICION FARMACEUTICA QUE LOS COMPRENDE.
CL2015003787A 2013-07-11 2015-12-30 Compuestos para la formación de pro-drogas CL2015003787A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361844985P 2013-07-11 2013-07-11

Publications (1)

Publication Number Publication Date
CL2015003787A1 true CL2015003787A1 (es) 2016-08-12

Family

ID=52277568

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2015003787A CL2015003787A1 (es) 2013-07-11 2015-12-30 Compuestos para la formación de pro-drogas

Country Status (12)

Country Link
US (2) US9745338B2 (es)
EP (1) EP3019172B1 (es)
JP (1) JP6449274B2 (es)
CN (1) CN105636592A (es)
AU (1) AU2014287049B2 (es)
CL (1) CL2015003787A1 (es)
IL (1) IL243385B (es)
MX (1) MX364743B (es)
PE (1) PE20160655A1 (es)
RU (1) RU2667942C2 (es)
WO (1) WO2015006691A1 (es)
ZA (1) ZA201600766B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201302368D0 (en) * 2013-02-11 2013-03-27 Univ Bath Compound
JP6449274B2 (ja) * 2013-07-11 2019-01-09 エベストラ インコーポレイテッド プロドラッグを生成する化合物
MX385372B (es) * 2015-03-23 2025-03-18 Evestra Inc Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos
CN108084075A (zh) * 2016-11-21 2018-05-29 天津大学 具有β-内酰胺酶抑制作用的脯氨酸衍生物
MX2020003470A (es) * 2017-10-19 2020-10-01 Evestra Inc Anticonceptivos de profarmacos de progestina de accion mas prolongada.
CN110862400A (zh) * 2018-08-27 2020-03-06 遵义医学院 喜树碱-羟基乙酸中间体的制备工艺
CN116854707B (zh) * 2023-05-08 2025-05-16 石家庄学院 一种环化小檗碱衍生物及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3461118A (en) 1966-10-17 1969-08-12 Syntex Corp 3beta-tetrahydrofuranyloxy - and 3beta-tetrahydropyranyloxyestra - 4,9(10) - dienes and -4,9(10),11-trienes,their preparation and intermediates thereof
JPS52148093A (en) * 1976-06-03 1977-12-08 Fujisawa Pharmaceut Co Ltd 7-(n-substituted-2-phenyl-glycineamido) cephalosporanic acid derivatives
US4260736A (en) * 1978-08-14 1981-04-07 Kureha Kagaku Kogyo Kabushiki Kaisha Steroid hormone-antitumor derivatives
US4615835A (en) 1983-11-17 1986-10-07 Stiftung Deutsches Krebsforschungs Zentrum Steroid esters of N-(2-halogenethyl)-N-nitroso-carbamoylamino and acids and peptides therefore, as well as method for preparing them
SE8802402D0 (sv) 1988-06-28 1988-06-28 Pharmacia Ab Novel esters
DE4029499A1 (de) 1990-09-18 1992-03-19 Boehringer Mannheim Gmbh Neue 17-(beta)-oestradiolderivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE4447715C2 (de) 1994-08-09 1998-02-05 Jenapharm Gmbh Verwendung von Estra-1,3,5(10)-trien-Derivaten zur hormonalen Behandlung von Prostatakarzinomen
DE4429397C2 (de) 1994-08-09 2003-11-20 Jenapharm Gmbh Estra-1,3,5(10)-trien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US5705495A (en) 1995-10-19 1998-01-06 Jenapharm Gmbh & Co. Kg. Sulfamate derivatives of 1,3,5(10)-estratriene derivatives, methods for their production and pharmaceuticals containing these compounds
FR2774989B1 (fr) 1998-02-18 2000-03-17 Adir Nouveaux cytotoxiques derives de l'oestradiol
WO2000027790A1 (en) * 1998-11-11 2000-05-18 Smithkline Beecham P.L.C. Mutilin compounds
US6958327B1 (en) 1999-11-02 2005-10-25 Schering, Ag 18 Norsteroids as selectively active estrogens
FR2801218B1 (fr) * 1999-11-23 2001-12-28 Hoechst Marion Roussel Inc Compositions pharmaceutiques comprenant de la trimegestone, leurs procedes de preparation ainsi que le conditionnement primaire les renfermant
DE10027887A1 (de) * 2000-05-31 2001-12-13 Jenapharm Gmbh Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6956031B2 (en) 2002-03-27 2005-10-18 Schering Aktiengesellschaft 11β-Substituted 19-nor-17-α-pregna-1,3,5(10)-trien-17β-ols with a 21,16α-lactone ring
US7414043B2 (en) 2002-06-11 2008-08-19 Schering Ag 9-α-substituted estratrienes as selectively active estrogens
US7534780B2 (en) * 2004-05-21 2009-05-19 Bayer Schering Pharma Aktiengesellschaft Estradiol prodrugs
US20050277625A1 (en) * 2004-05-21 2005-12-15 Ralf Wyrwa Estriol and estetrol prodrugs
DE102004025966A1 (de) * 2004-05-21 2005-12-15 Schering Ag Estradiol-Prodrugs
US7470787B2 (en) * 2005-07-11 2008-12-30 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
US20070135399A1 (en) * 2005-11-30 2007-06-14 Ralf Wyrwa Heteroaromatic sulphonamide prodrugs
US20070135375A1 (en) 2005-11-30 2007-06-14 Ralf Wyrwa Sulfamoyl sulfonate prodrugs
LT1976828T (lt) * 2005-12-29 2017-04-25 Celtaxsys, Inc. Diamino dariniai, kaip leukotrieno a4 hidrolazės inhibitoriai
US7601844B2 (en) * 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
WO2008113851A2 (en) * 2007-03-22 2008-09-25 Solvay Pharmaceuticals Gmbh Novel c11 modified retrosteroids as progesterone receptor modulator compounds
WO2009005677A2 (en) * 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
JP5509104B2 (ja) * 2008-03-14 2014-06-04 エグゼリクシス， インコーポレイテッド １１β−ＨＳＤ１モジュレータとしてのアザビシクロ［３．２．１］オクチル誘導体
US8461163B2 (en) * 2008-03-31 2013-06-11 Takeda Pharmaceutical Company Limited Substituted N-(pyrazolo[1,5-a]pyrimidin-5-yl)amides as inhibitors of apoptosis signal-regulating kinase 1
US20100061976A1 (en) 2008-07-24 2010-03-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing osteoporosis by reducing follicle stimulating hormone to cyclic physiological levels in a mammalian subject
CN102180822B (zh) 2009-12-14 2014-08-13 罗门哈斯电子材料有限公司 磺酰光酸产生剂和包含该磺酰光酸产生剂的光刻胶
CN102079771B (zh) 2010-12-10 2012-10-03 郑州大学 具有抗肿瘤活性的雌甾氨基酸酯化合物及其合成方法
CN102127137A (zh) 2010-12-10 2011-07-20 郑州大学 制备雌甾氨基酸酯的中间体化合物及其合成方法
US20130029953A1 (en) * 2011-07-28 2013-01-31 Klaus Nickisch Progesterone antagonists
WO2013029338A1 (en) 2011-09-01 2013-03-07 Glaxo Group Limited Novel compounds
JP6449274B2 (ja) * 2013-07-11 2019-01-09 エベストラ インコーポレイテッド プロドラッグを生成する化合物
MX385372B (es) * 2015-03-23 2025-03-18 Evestra Inc Nuevos agentes citotóxicos que preferentemente se dirigen al factor inhibidor de leucemia (lif) para el tratamiento de malignidades y como nuevos agentes anticonceptivos

Also Published As

Publication number Publication date
EP3019172B1 (en) 2019-09-25
US20170349624A1 (en) 2017-12-07
JP2016525101A (ja) 2016-08-22
JP6449274B2 (ja) 2019-01-09
MX364743B (es) 2019-05-06
EP3019172A1 (en) 2016-05-18
US10273263B2 (en) 2019-04-30
US20150018322A1 (en) 2015-01-15
IL243385A0 (en) 2016-02-29
EP3019172A4 (en) 2017-03-29
RU2016102182A3 (es) 2018-04-02
AU2014287049B2 (en) 2019-09-26
RU2016102182A (ru) 2017-08-16
RU2667942C2 (ru) 2018-09-27
US9745338B2 (en) 2017-08-29
IL243385B (en) 2019-08-29
AU2014287049A1 (en) 2016-02-18
CN105636592A (zh) 2016-06-01
PE20160655A1 (es) 2016-07-08
MX2016000243A (es) 2017-03-03
WO2015006691A1 (en) 2015-01-15
ZA201600766B (en) 2017-03-29

Similar Documents

Publication Publication Date Title
CL2015003787A1 (es) Compuestos para la formación de pro-drogas
BR112016006209A2 (pt) composição de polímero termoplástico
CU20170172A7 (es) 4,6-diaminoquinolin-3-carbonitrilos sustituidos útiles como agentes analgésicos, antipiréticos o antiinflamatorios y antineoplásicos
PT3216448T (pt) Composições veterinárias orais parasiticidas que compreendem agentes, métodos e métodos ativos que agem sistemicamente
CL2018001710A1 (es) Derivados de pirazol activos como pesticida.
GT201400297A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CU20160052A7 (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
UY35467A (es) Compuestos orgánicos
MX2015008627A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
CL2016000882A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15).
GT201600085A (es) Composiciones y métodos para modular los receptores x farnesoides
CU20170105A7 (es) Derivados de nucleosidos sustituidos útiles como agentes antineoplásicos
UY35353A (es) Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer
MX2015011520A (es) Composiciones antimicrobianas.
CU24397B1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b
EA201591003A1 (ru) Производные бороновой кислоты и их терапевтическое применение
CU20140081A7 (es) Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO7180201A2 (es) Inhibidores de neprilisina
UA122520C2 (uk) Кристалічна форма 2-[4-(4-хлорфенокси)-2-(трифторметил)феніл]-1-(1,2,4-триазол-1-іл)пропан-2-олу, агрохімічна композиція, застосування та спосіб боротьби зі шкідливими грибами
BR112016000489A2 (pt) composto, composição farmacêutica que o compreende, uso da composição e métodos para fabricar compostos
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
MX2016002077A (es) Inhibidores de la proteína regulada por glucosa 94 (gpr94) selectivos y usos de los mismos.
EP3034613A4 (en) NOVEL SOPHOROLIPIDE COMPOUND AND COMPOSITION THEREOF
CL2016001367A1 (es) Gamma-dicetonas como activadores de la ruta de señalización de wnt/beta-catenina (divisional de solicitud n° 2363-2015).
DOP2016000007A (es) Pirazolpiridinas sustituidas